- Medical_Professionals
- Medical_students
- Nurses
2nd Exploring DNA Repair Pathways as Targets for Cancer Therapy Conference
Defect in DNA damage repair and checkpoint control is the underlying mechanism for tumorigenesis, since it allows the accumulation of multiple genetic alternations, which are essential for the initiation of tumorigenesis. This has been clearly illustrated to be the cause of several human cancer-prone syndromes and also revealed by recent human genome studies. On the other hand, defective DNA repair and checkpoint activation also make cancer cells more vulnerable for particular DNA damaging agents or inhibitors that specifically disrupt some of these checkpoint pathways. With the increasing understanding of defects in DNA repair and checkpoint control in tumorigenesis, there are extensive interests in exploring these deficiencies, especially taking advantage of the synthetic lethality concept and targeting particular DNA repair and checkpoint pathways for cancer therapy. The purpose of this conference is to bring together basic, translational and clinical investigators and discuss the current and future directions, opportunities and obstacles in the development of these anti-cancer modalities and how to best apply these concepts in clinical practice.
Key Sessions
Highlight recent advances in the field of DNA damage repair
Identify novel targets in DNA repair and checkpoint pathways
Explore the concept of synthetic lethality for cancer treatment
Assess the therapeutic potential of new anti-cancer modalities
Learn mechanisms of therapeutic resistance and ways to improve cancer therapy
Target Audience
This conference explores topics that should appeal to basic, translational and clinical investigators as well as clinicians ranging from academics to industry. The audience will benefit greatly from the interactions with experts in the fields of DNA damage response, drug development and clinical trials.
2017 DNA Poster Prize
The conference chairs will be awarding 3 poster prizes for the best poster display and presentation. To be in with a chance of winning, submit your poster by 08 December 2016. The winners will be selected shortly after the Poster Session and each winner will receive $250!
Robert Abraham (Pfizer)
Christopher Bakkenist (University of Pittsburgh)
Michelle Barton (MD Anderson Cancer Center)
Lauren Averett Byers (MD Anderson Cancer Center)
Dipanjan Chowdhury (Dana-Farber Cancer Institute)
Karlene Cimprich (Stanford University)
Giulio Draetta (MD Anderson Cancer Center)
Daniel Durocher (The Lunenfeld-Tanenbaum Research Institute)
Yi Fan (University of Pennsylvania)
Shridar Ganesan (Rutgers Cancer Institute of New Jersey)
Jean Gautier (Columbia University)
Reuben Harris (University of Minnesota)
Robert Hromas (University Of Florida)
Chuan-Yuan Li (Duke University Medical Center)
Zhenkun Lou (Mayo Clinic)
Jac A. Nickoloff (Colorado State University)
Mark J O'Connor (AstraZeneca)
Akihiro Ohashi (Takeda)
Yves Pommier (NCI)
Brendan Price (Dana-Farber Cancer Institute)
Elizabeth Swisher (University of Washington)
Lorraine Symington (Columbia University)
Matthew Weitzman (The Children’s Hospital of Philadelphia)
Richard Wood (MD Anderson Cancer Center)
Fen Xia (Ohio State University)
USD
2016-12-01
Group registrations not allowed
Accompanying persons not allowed
We don’t accept Online Abstracts
Fiesta Americana Condesa
Cancun, Mexico
Submission Info
Office address
Unit 5D, Lynx Business Park
Fordham Road
Snailwell
Newmarket
CB8 7NY
United Kingdom
Office numbers
Tel: +44 (0) 1638 724137
Fax: +44 (0) 1638 724135
Office contact
Skype: Fusion.Conferences
Email: admin@fusion-conferences.com
Office address
Unit 5D, Lynx Business Park
Fordham Road
Snailwell
Newmarket
CB8 7NY
United Kingdom
Office numbers
Tel: +44 (0) 1638 724137
Fax: +44 (0) 1638 724135
Office contact
Skype: Fusion.Conferences
Email: admin@fusion-conferences.com